Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis of CLEAR ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for ...

Medifast, the health and wellness company known for its science-backed, coach-guided lifestyle system, continues to lead the charge in addressing the growing health crisis of metabolic dysfunction by ...

New information to be presented on the study design and methodology of Purespring’s Phase I/II trial of PS-002, an AAV-based ...

Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and ...

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine ...

CNW/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, ...

MRT-8102 is a selective, potent, and durable NEK7 degrader. Activation of the NLRP3 inflammasome critically depends on NEK7. Administration of MRT-8102 led to inhibition of NLRP3 inflammasome in vitro ...

OSE-Cytomask® platform is an innovative proprietary non-cleavable linker technology to create a new class of regulated and targeted cytokine therapeutics that enables precise cytokine activation on ...

SYRACUSE, NY / ACCESS Newswire / November 11, 2025 / Repair Biotechnologies, Inc. ( today announced the recent presentation of preclinical data at American Heart Association's (AHA) Scientific ...

SYRACUSE, NY / ACCESS Newswire / November 11, 2025 / Repair Biotechnologies, Inc. ( today announced the recent presentation of preclinical data at American Heart ...